NO990518L - Langtidsvirkende medikamenter og farmas°ytiske sammensetninger som omfatter disse - Google Patents

Langtidsvirkende medikamenter og farmas°ytiske sammensetninger som omfatter disse

Info

Publication number
NO990518L
NO990518L NO990518A NO990518A NO990518L NO 990518 L NO990518 L NO 990518L NO 990518 A NO990518 A NO 990518A NO 990518 A NO990518 A NO 990518A NO 990518 L NO990518 L NO 990518L
Authority
NO
Norway
Prior art keywords
carboxyl
radical
amino
aryl
alkyl
Prior art date
Application number
NO990518A
Other languages
English (en)
Norwegian (no)
Other versions
NO990518D0 (no
Inventor
Matityahu Fridkin
Yoram Shechter
Eytan Gershonov
Original Assignee
Yeda Res & Dev
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yeda Res & Dev filed Critical Yeda Res & Dev
Publication of NO990518D0 publication Critical patent/NO990518D0/no
Publication of NO990518L publication Critical patent/NO990518L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/555—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound pre-targeting systems involving an organic compound, other than a peptide, protein or antibody, for targeting specific cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/02—Local antiseptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
NO990518A 1996-08-07 1999-02-04 Langtidsvirkende medikamenter og farmas°ytiske sammensetninger som omfatter disse NO990518L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IL11902996A IL119029A0 (en) 1996-08-07 1996-08-07 Long-acting drugs and pharamaceutical compositions comprising them
PCT/IL1997/000265 WO1998005361A2 (en) 1996-08-07 1997-08-05 Long-acting drugs and pharmaceutical compositions comprising them

Publications (2)

Publication Number Publication Date
NO990518D0 NO990518D0 (no) 1999-02-04
NO990518L true NO990518L (no) 1999-04-06

Family

ID=11069166

Family Applications (1)

Application Number Title Priority Date Filing Date
NO990518A NO990518L (no) 1996-08-07 1999-02-04 Langtidsvirkende medikamenter og farmas°ytiske sammensetninger som omfatter disse

Country Status (18)

Country Link
US (1) US6504005B1 (th)
EP (1) EP1019089B1 (th)
JP (1) JP4416184B2 (th)
KR (1) KR20000029806A (th)
CN (1) CN1227501A (th)
AT (1) ATE308998T1 (th)
AU (1) AU725468B2 (th)
BR (1) BR9711045A (th)
CA (1) CA2261835C (th)
CZ (1) CZ36999A3 (th)
DE (1) DE69734607T2 (th)
DK (1) DK1019089T3 (th)
ES (1) ES2252787T3 (th)
HU (1) HUP0000809A2 (th)
IL (3) IL119029A0 (th)
NO (1) NO990518L (th)
NZ (1) NZ333845A (th)
WO (1) WO1998005361A2 (th)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL139400A0 (en) * 2000-11-01 2001-11-25 Yeda Res & Dev Long-acting cytokine derivatives and pharmaceutical compositions comprising them
AU2002239384B2 (en) * 2000-12-13 2007-01-11 Eli Lilly And Company Chronic treatment regimen using glucagon-like insulinotropic peptides
PL211116B1 (pl) 2001-10-19 2012-04-30 Idexx Lab Komozycja do podawania ssakowi związku farmakologicznie czynnego i sposób wytwarzania preparatu do wstrzyknięć
US6946137B2 (en) * 2001-10-19 2005-09-20 Idexx Laboratories, Inc. Methods for the controlled delivery of pharmacologically active compounds
US20030171285A1 (en) * 2001-11-20 2003-09-11 Finn Rory F. Chemically-modified human growth hormone conjugates
BE1015608A6 (fr) * 2003-07-15 2005-06-07 Messadek Jallal Traitement des arterites.
JP4033382B2 (ja) * 2002-04-08 2008-01-16 久光製薬株式会社 インスリン投与装置
EP1583972B1 (en) * 2003-01-16 2010-11-24 caprotec bioanalytics GmbH Methods for identifying drug non-target proteins
WO2004089280A2 (en) * 2003-04-08 2004-10-21 Yeda Research And Development Co. Ltd. Reversible pegylated drugs
EP1615632B1 (fr) * 2003-04-17 2006-12-06 Jallal Messadek Formulations orales flottantes pour la liberation controlee de la betaine
AU2004261353B2 (en) 2003-08-05 2009-12-10 Novo Nordisk A/S Novel insulin derivatives
BE1016128A6 (fr) * 2004-07-22 2006-03-07 Messadek Jallal Combinaisons therapeutiques
US7282487B2 (en) * 2004-10-28 2007-10-16 Idexx Laboratories Method for treating bacterial infections in horses or pigs with tilmicosin
WO2006050581A2 (en) * 2004-11-10 2006-05-18 Jallal Messadek Betaine as agent against arthropod - or mosquito -borne diseases
RU2007143510A (ru) * 2005-04-27 2009-06-10 Яллал МЕССАДЕК (BE) Инсулиновые композиции
EP1969004B1 (en) 2005-12-28 2011-08-10 Novo Nordisk A/S Compositions comprising an acylated insulin and zinc and method of making the said compositions
JP5552046B2 (ja) 2007-06-13 2014-07-16 ノボ・ノルデイスク・エー／エス インスリン誘導体を含有する薬学的製剤
WO2009065193A1 (en) * 2007-11-21 2009-05-28 Jallal Messadek Treatment of aspirin resistance with betaine and/or betaine enriched molasses
HUE032284T2 (en) 2008-03-18 2017-09-28 Novo Nordisk As Protease-stabilized, acylated insulin analogues
CN102076331B (zh) 2008-06-26 2013-12-18 普罗林科斯有限责任公司 具有可控的药物释放速率的前药和药物-大分子轭合物
EP2344200A2 (en) * 2008-09-19 2011-07-20 Nektar Therapeutics Modified therapeutics peptides, methods of their preparation and use
EP2350118B1 (en) * 2008-09-19 2016-03-30 Nektar Therapeutics Carbohydrate-based drug delivery polymers and conjugates thereof
JP5775820B2 (ja) * 2008-10-21 2015-09-09 バクスター・インターナショナル・インコーポレイテッドＢａｘｔｅｒ Ｉｎｔｅｒｎａｔｉｏｎａｌ Ｉｎｃｏｒｐ０Ｒａｔｅｄ 遊離可能ｐｅｇ試薬を有するプロドラッグｐｅｇタンパク質結合体において活性成分（インビトロ脱ペグ化）を決定する方法
CN102202683A (zh) 2008-10-30 2011-09-28 诺沃-诺迪斯克有限公司 用少于每日一次的注射频率注射胰岛素来治疗糖尿病
CN102413843A (zh) 2009-03-05 2012-04-11 阿森迪斯药物股份有限公司 干扰素α载体前药
WO2011013128A2 (en) 2009-07-31 2011-02-03 Yeda Research And Development Co. Ltd. Vectors for delivery of neurotherapeutics to the central nervous system
WO2011140393A1 (en) * 2010-05-05 2011-11-10 Prolynx Llc Controlled release from macromolecular conjugates
DK2632478T3 (da) 2010-10-27 2019-10-07 Novo Nordisk As Behandling af diabetes melitus under anvendelse af insulinindsprøjtninger indgivet med varierende indsprøjtningsintervaller
EP2490378B1 (en) 2011-02-18 2014-07-09 NTT DoCoMo, Inc. Apparatus and method for determining a control unit using feasibility requests and feasibility responses
EP2714070B1 (en) 2011-06-02 2024-03-20 OPKO Biologics Ltd. Long-acting glp-1/glucagon receptor agonists
US10166295B2 (en) 2011-06-02 2019-01-01 Opko Biologics Ltd. Pegylated OXM variants
EP2836508B1 (en) 2012-04-11 2016-06-29 Novo Nordisk A/S Insulin formulations
MX362432B (es) 2012-06-04 2019-01-17 Opko Biologics Ltd Variantes de oxm pegilada.
WO2014009316A1 (en) 2012-07-09 2014-01-16 Novo Nordisk A/S Novel use of insulin derivatives
EP2991672A1 (en) 2013-04-30 2016-03-09 Novo Nordisk A/S Novel administration regime
ES2886837T3 (es) 2016-12-16 2021-12-21 Novo Nordisk As Composiciones farmacéuticas que contienen insulina
US10335464B1 (en) 2018-06-26 2019-07-02 Novo Nordisk A/S Device for titrating basal insulin
US12441776B2 (en) 2018-11-30 2025-10-14 Eirgen Pharma Ltd. Oxyntomodulin peptide analog formulations
US20200254065A1 (en) 2019-02-11 2020-08-13 Opko Biologics Ltd. Long-acting glp-2 analogs
CN114096269B (zh) 2019-07-12 2024-06-11 诺和诺德股份有限公司 高浓度胰岛素制剂
WO2021067458A1 (en) 2019-09-30 2021-04-08 Beijing Xuanyi Pharmasciences Co., Ltd. Protein-macromolecule conjugates and methods of use thereof
CN113773398B (zh) * 2020-06-10 2023-05-23 宁波鲲鹏生物科技有限公司 一种德谷胰岛素衍生物及其应用
CN117551008B (zh) * 2023-11-10 2025-10-17 沈阳药科大学 一种去铁胺偶联物及其制备方法和应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU206890B (en) * 1986-10-13 1993-01-28 Sandoz Ag Process for producing sugar-modified somatostatin peptide derivatives and pharmaceutical compositions containing them as active components
GB8717446D0 (en) 1987-07-23 1987-08-26 Merck Sharp & Dohme Chemical compounds
US6313094B1 (en) * 1990-12-11 2001-11-06 Japan Energy Corporation β-amino-α-hydroxycarboxylic acid derivatives and HIV protease inhibitors
JPH0687887A (ja) * 1992-08-19 1994-03-29 Upjohn Co:The ペプチドのエナミン誘導体およびそれをプロドラッグとして含有するペプチド製剤
CA2142985A1 (en) 1993-06-25 1995-01-05 Kenji Shibata Endothelin-antagonizing peptide
US5880131A (en) * 1993-10-20 1999-03-09 Enzon, Inc. High molecular weight polymer-based prodrugs
AU1919595A (en) 1994-02-09 1995-08-29 Brigham And Women's Hospital Gel-forming polypeptide derivatives
DE4437604A1 (de) * 1994-10-21 1996-04-25 Basf Ag Konjugate aus einem Poly- oder Oligopeptid und einer niedermolekularen lipophilen Verbindung
AU5377296A (en) * 1995-03-30 1996-10-16 Southpac Trust International, Inc. Self-erecting container which is collapsible to be substanti ally flat
US5688992A (en) 1995-03-31 1997-11-18 The United States Of America As Represented By The Department Of Health And Human Services O-malonyltryrosyl compounds, O-malonyltryrosyl compound-containing peptides, and use thereof
US5846934A (en) * 1996-02-20 1998-12-08 American Cyanamid Company Pure somatostatin antagonist and methods of use thereof
US6057297A (en) * 1996-08-06 2000-05-02 Polifarma S.P.A. Inhibitor compounds of zinc-dependent metalloproteinases associated with pathological conditions, and therapeutic use thereof

Also Published As

Publication number Publication date
CA2261835C (en) 2008-07-29
JP4416184B2 (ja) 2010-02-17
WO1998005361A3 (en) 1998-06-18
CA2261835A1 (en) 1998-02-12
EP1019089A2 (en) 2000-07-19
EP1019089B1 (en) 2005-11-09
NZ333845A (en) 2000-09-29
DE69734607T2 (de) 2006-08-03
HUP0000809A2 (hu) 2000-11-28
IL128274A (en) 2006-08-01
DK1019089T3 (da) 2006-03-13
BR9711045A (pt) 1999-08-17
ATE308998T1 (de) 2005-11-15
KR20000029806A (ko) 2000-05-25
IL119029A0 (en) 1996-11-14
JP2000515542A (ja) 2000-11-21
CN1227501A (zh) 1999-09-01
US6504005B1 (en) 2003-01-07
CZ36999A3 (cs) 1999-07-14
WO1998005361A2 (en) 1998-02-12
AU3706097A (en) 1998-02-25
AU725468B2 (en) 2000-10-12
ES2252787T3 (es) 2006-05-16
IL128274A0 (en) 1999-11-30
NO990518D0 (no) 1999-02-04
DE69734607D1 (de) 2005-12-15

Similar Documents

Publication Publication Date Title
WO1998005361A3 (en) Long-acting drugs and pharmaceutical compositions comprising them
HUP9903766A2 (en) Pyridyl alkene- and pyridyl alkine- acid amides, use of them as cytostatics and immunosuppressives, process for their preparation and pharmaceuticals containing the same
AU570067B2 (en) Chromanylalkoxybenzyl substituted thiazolidines
DK0623347T3 (da) Anvendelse af bisphosphonsyrederivater til fremstilling af et lægemiddel til fremme af knogleheling
AU5188598A (en) Substituted aminoalkane phosphonic acids
YU50302A (sh) Nova heterociklična jedinjenja, njihove soli i njihova primena u medicini
HUP0101999A2 (hu) 4-Hidroxi-kinolin-3-karboxamid- és -hidrazid-származékok, ezeket tartalmazó gyógyászati készítmények, valamint e vegyületek alkalmazása
TR199700178A2 (tr) Tümörlerin ve iltihapli hastaliklarin tedavisine yönelik yeni pro ilaclar.
HUP9801676A2 (hu) Új 2,3-dioxo-1,2,3,4-tetrahidrokinoxalinil-származékok
HUP0002404A2 (hu) Aminosavszármazékok, hatóanyagként ezeket tartalmazó gyógyszerkészítmények, eljárás előállításukra és alkalmazásuk
NO172233C (no) Analogifremgangsmaate for fremstilling av anti-aterosklerotisk aktive diarylforbindelser
TW355705B (en) Substituted benzyloxycarbonylguanidines, process for their preparation, their medical use and pharmaceutical composition containing them
ES2109988T3 (es) Derivados cefalosporinicos.
PT77309A (de) Isochinolinderivate verfahren zu ihrer herstellung pharmazeutische praeparate auf basis dieser verbindungen und ihre verwendung
TR199801196T2 (xx) Biyolojik aktif benzotiyazolon etanaminler.
HUP0204217A2 (en) Novel a-500359 derivatives
HUP0000934A1 (hu) 4-{2-[N-(3-Fenoxi-2-hidroxi)-propil-amino]-etil}-anilid-származékok és az ezeket tartalmazó gyógyászati készítmények
EP0299076A4 (en) 5-hydroxyindole-3-carboxamide compound and medicinal use thereof
DE60017194D1 (de) Verfahren zur herstellung von carbapenem-antibiotika zubereitungen
ATE16102T1 (de) Sulfonylharnstoffe, verfahren zu ihrer herstellung, pharmazeutische praeparate auf basis dieser verbindungen und ihre verwendung.
ATE22284T1 (de) 2-aminomethyl-6-sulfamoylphenolderivate, verfahren zu ihrer herstellung, ihre verwendung sowie pharmazeutische praeparate auf basis dieser verbindungen.
BR0317409A (pt) Compostos cicloalquileno amida 2-piridila e 2-pirimidila, composição farmacêutica compreendendo os mesmos e uso dos referidos compostos
DE59305351D1 (de) Neue acyclische amidingruppen-haltige diphosphonsäurederivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel
RU99105128A (ru) Лекарственные средства с длительным сроком действия и содержащие их композиции
HUP9801985A2 (hu) Cisztinszármazékok alkalmazása restenózis gyógyítására használható gyógyszerkészítmények előállítására

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application